Rosetta Gets Medicare Coverage for mets2 Assay; Stock Soars | GenomeWeb

NEW YORK (GenomeWeb News) – Rosetta Genomics today said that Novitas, a designated Medicare contractor, has informed the firm that it plans to cover its miRview mets2 assay for all Medicare beneficiaries.

Rosetta's shares climbed as high as $7.84 in Wednesday trade on the Nasdaq, before closing at $4.99, up 208 percent.

The miRview mets2 test identifies tumor of origin in primary and metastatic cancer including cancer of unknown or uncertain primary.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.